share_log

6-K: Novo Nordisk A/S - Share Repurchase Programme

6-K: Novo Nordisk A/S - Share Repurchase Programme

6-K：諾和諾德-股票回購計劃
美股SEC公告 ·  10/28 08:53

Moomoo AI 已提取核心訊息

Novo Nordisk A/S, a leading global healthcare company, has reported progress on its share repurchase program. The program, which was initiated on August 7, 2024, is part of a larger DKK 20 billion buyback plan set to occur over a 12-month period starting February 6, 2024. As of October 25, 2024, Novo Nordisk has repurchased 13,597,148 B shares at an average price of DKK 875.31 per share, totaling DKK 11,901,762,964. The transactions from October 21 to October 25, 2024, resulted in the acquisition of an additional 233,500 B shares for DKK 186,260,090. Following these purchases, Novo Nordisk holds 14,925,779 B shares as treasury shares, which represents 0.3% of the share capital. The company's shares are traded on Nasdaq Copenhagen and its ADRs on the New York Stock Exchange. Novo Nordisk's commitment to defeating serious chronic diseases is underscored by its extensive global presence, with approximately 69,000 employees in 80 countries and product availability in around 170 countries.
Novo Nordisk A/S, a leading global healthcare company, has reported progress on its share repurchase program. The program, which was initiated on August 7, 2024, is part of a larger DKK 20 billion buyback plan set to occur over a 12-month period starting February 6, 2024. As of October 25, 2024, Novo Nordisk has repurchased 13,597,148 B shares at an average price of DKK 875.31 per share, totaling DKK 11,901,762,964. The transactions from October 21 to October 25, 2024, resulted in the acquisition of an additional 233,500 B shares for DKK 186,260,090. Following these purchases, Novo Nordisk holds 14,925,779 B shares as treasury shares, which represents 0.3% of the share capital. The company's shares are traded on Nasdaq Copenhagen and its ADRs on the New York Stock Exchange. Novo Nordisk's commitment to defeating serious chronic diseases is underscored by its extensive global presence, with approximately 69,000 employees in 80 countries and product availability in around 170 countries.
諾和諾德集團是全球領先的醫療保健公司，已報告其股票回購計劃的進展。該計劃始於2024年8月7日，是一項更大規模的200億丹麥克朗回購計劃的一部分，計劃於2024年2月6日開始，爲期12個月。截至2024年10月25日，諾和諾德已以每股875.31丹麥克朗的平均價格回購了135,971,480億股，總價值爲119,017,629,640丹麥克朗。從2024年10月21日至10月25日的交易中，導致再購入額外的2,335,000億股，價格爲186,260,090丹麥克朗。在這些購買之後，諾和諾德持有149,257,790億股作爲庫存股，佔股本的0.3%。該公司股票在納斯達克哥本哈根交易，其美國存托股票在紐約證券交易所交易。諾和諾德致力於戰勝嚴重慢性疾病，其全球範圍廣泛，員工約69,000人，分佈在80個國家，產品在約170個國家銷售。
諾和諾德集團是全球領先的醫療保健公司，已報告其股票回購計劃的進展。該計劃始於2024年8月7日，是一項更大規模的200億丹麥克朗回購計劃的一部分，計劃於2024年2月6日開始，爲期12個月。截至2024年10月25日，諾和諾德已以每股875.31丹麥克朗的平均價格回購了135,971,480億股，總價值爲119,017,629,640丹麥克朗。從2024年10月21日至10月25日的交易中，導致再購入額外的2,335,000億股，價格爲186,260,090丹麥克朗。在這些購買之後，諾和諾德持有149,257,790億股作爲庫存股，佔股本的0.3%。該公司股票在納斯達克哥本哈根交易，其美國存托股票在紐約證券交易所交易。諾和諾德致力於戰勝嚴重慢性疾病，其全球範圍廣泛，員工約69,000人，分佈在80個國家，產品在約170個國家銷售。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    熱議
    美股
    股票代碼最新價升跌幅

    暫無數據

    資訊熱榜
    更新時間